News

Feb 7, 2023

Fractyl Health gibt die kommerzielle Verfügbarkeit von Revita in Deutschland und das® erste erfolgreiche Verfahren beim 25. Internationalen Endoskopie-Symposium in Düsseldorf bekannt

...

Read More

Feb 7, 2023

Fractyl Health Announces Commercial Availability of Revita® in Germany and Successful First Procedure at 25th Düsseldorf International Endoscopy Symposium

...

Read More

Jan 31, 2023

Fractyl Health Provides Clinical Update on 24-Week Data from Open Label REVITA-T2Di Cohort

...

Read More

Dec 5, 2022

Fractyl Health Announced Positive Proof-of-Concept Data of Pancreatic GLP-1 Gene Therapy in a Type 2 Diabetes Animal Model at the 20th World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease

...

Read More

Nov 2, 2022

Fractyl Health Initiates Landmark Scientific Partnership to Study Root Cause Mechanisms Underlying Type 2 Diabetes

...

Read More

May 22, 2022

Fractyl Health Presents New Mechanistic Data on Revita® DMR in Type 2 Diabetes

...

Read More

May 17, 2022

Fractyl Health to Present New Data on Revita® DMR in Type 2 Diabetes at Digestive Disease Week 2022

Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes (T2D), will share new data in an oral presentation during the 2022 Digestive Diseas...

Read More

Apr 4, 2022

Fractyl Health Announces FDA IDE Approval to Begin Revitalize-2 Pivotal Study Designed for Patients with Type 2 Diabetes (T2D) Who Are Not Yet on Insulin

...

Read More

Feb 8, 2022

Fractyl Health Receives Reimbursement Authorization in Germany for Revita DMR® System

...

Read More

Feb 1, 2022

Fractyl Health Publishes Two-Year Durability Data After a Single Revita DMR® Therapeutic Procedure in Patients with Type 2 Diabetes

...

Read More